Answers are grounded in this paper and cite their sources.
Detergent-mediated viral inactivation is an important process step for ensuring viral safety of parenteral biotherapeutics, including plasma proteins and monoclonal antibodies (mAb). The conventional Triton™ X-100 detergent has ecological toxicity concerns and REACH classification that mandate replacement in the biopharmaceutical industry. Criteria for a replacement detergent include viral inactivation efficacy, acceptable safety and biodegradation profile, process removal and quality suitable for parenteral drug product manufacturing. A non-ionic, C11-15 secondary alcohol ethoxylate, Deviron ® 13-S9 detergent, has been demonstrated to meet the necessary requirements for detergent performance. Benchmarking studies with Triton™ X-100 demonstrate comparable performance with a panel of enveloped viruses in multiple matrices, including human IgG, clarified cell culture harvest, and fractionated plasma. Deviron ® 13-S9 detergent demonstrated viral inactivation efficiency comparable to or better than, Triton™ X-100 detergent, achieving > 5 log reduction values (LRV). Critical micelle concentration (CMC) was determined across different temperatures and media. Deviron ® 13-S9 detergent was demonstrated to be readily biodegradable according to OECD 301B guidelines. Effective removal with typical chromatography processes used in downstream purification was confirmed. These findings support Deviron ® 13-S9 detergent as a viable alternative to Triton™ X-100 detergent, ensuring robust viral inactivation, environmental compatibility, and alignment with regulatory requirements.
No takes yet. Share an insight, caveat, or question.
Banerjee et al. (2024) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: